The comparison of Zn(II) arginine dithiocarbamate cytotoxicity in T47D breast cancer and fibroblast cells

Breast Dis. 2021;40(S1):S55-S61. doi: 10.3233/BD-219008.

Abstract

Background: With essential metals being studied and developed as anticancer agents, this study aims to explore the anticancer activity of Zn(II) arginine dithiocarbamate in the T47D and fibroblast cell lines.

Method: The Zn(II) arginine dithiocarbamate complex was prepared by the in situ method and characterized using infra-red spectroscopy, melting point, X-ray fluorescence, and X-ray diffraction instruments. The complex compound was tested for its cytotoxicity to the T47D breast cancer and fibroblast cell lines.

Results: The cytotoxicity of the Zn(II) arginine dithiocarbamate complex to the T47D breast cancer cell line obtained IC50 = 3.16 μg/mL, while cisplatin obtained IC50 = 28.18 μg/mL. The cytotoxicity of the Zn(II) arginine dithiocarbamate complex to fibroblast cells obtained IC50 = 8709.63 μg/mL.

Conclusion: The Zn(II) arginine dithiocarbamate complex has increased active cytotoxicity compared to cisplatin in inducing morphological changes in the T47D breast cancer cell line and is relatively non-toxic to fibroblast cells.

Keywords: Complexes; Zn(II) arginine dithiocarbamate; breast cancer; T47D; cytotoxic.

Publication types

  • Comparative Study

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Arginine / chemistry
  • Arginine / pharmacology*
  • Breast Neoplasms / drug therapy
  • Cell Line, Tumor
  • Congresses as Topic
  • Female
  • Fibroblasts / drug effects*
  • Humans
  • Thiocarbamates / chemistry
  • Thiocarbamates / pharmacology*
  • Zinc / chemistry
  • Zinc / pharmacology*

Substances

  • Antineoplastic Agents
  • Thiocarbamates
  • Arginine
  • Zinc